Chediak-Higashi Syndrome
10
1
3
3
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
30.0%
3 terminated out of 10 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Study of Chediak-Higashi Syndrome
Immune Disorder HSCT Protocol
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Baby Detect : Genomic Newborn Screening
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
Stem Cell Transplant for Immunologic or Histiocytic Disorders
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders